Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.76 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267969 | 0.90 | CYP3A4 (0.76) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 | |
| SCHEMBL1886524 | 0.90 | CYP2C9 (1.00) | CYP2C9CYP2C19CYP3A4CSF1R | |
| SCHEMBL1886661 | 0.89 | CYP2C19 (0.64) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 | |
| SCHEMBL1266441 | 0.89 | CYP3A4 (0.79) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 | |
| SCHEMBL1267739 | 0.89 | CYP2C9 (0.81) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 | |
| SCHEMBL1895330 | 0.88 | CYP3A4 (0.83) | CYP2C9CYP2C19CYP3A4CSF1RKIT | |
| SCHEMBL12251826 | 0.87 | CYP2C19 (0.62) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 | |
| SCHEMBL1883905 | 0.87 | CYP3A4 (1.00) | CYP2C9CYP2C19CYP3A4CSF1RKIT | |
| SCHEMBL1895407 | 0.87 | CYP3A4 (0.80) | CYP2C9CYP2C19CYP3A4CSF1RKIT | |
| SCHEMBL1888231 | 0.86 | CSF1R (0.72) | CYP2C9CYP2C19CYP3A4CSF1RCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2013-10-17 | — | — | US | claimed |
| US-8461169-B2 | Compounds modulating c-fms and/or c-kit activity | PLEXXIKON INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8404700-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | claimed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | claimed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | claimed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | claimed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-4295912-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Daiichi Sankyo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-10123998-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2018-03-01 | — | — | US | disclosed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123998-B2 | Kinase modulation, and indications therefor | FLT3, FLT4, FLT1 | CYP2C9 4286/4885CYP2C19 3521/4885CYP3A4 4236/4885 |
| US-20130274259-A1 | KINASE MODULATION AND INDICATIONS THEREFOR | FLT3, MET, BTK | CYP2C9 4752/4885CYP2C19 4477/4885CYP3A4 4525/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CYP2C9 4122/4885CYP2C19 3327/4885CYP3A4 3847/4885 |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP2C9 4122/4885CYP2C19 3327/4885CYP3A4 3847/4885 |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | CYP2C9 4286/4885CYP2C19 3521/4885CYP3A4 4236/4885 |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | KIT, FLT3, FER | CYP2C9 4149/4885CYP2C19 3400/4885CYP3A4 4163/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP2C9 4093/4885CYP2C19 3359/4885CYP3A4 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.